home / stock / phar / phar quote
Last: | $9.63 |
---|---|
Change Percent: | 3.1% |
Open: | $9.29 |
Close: | $9.34 |
High: | $9.64 |
Low: | $9.28 |
Volume: | 3,321 |
Last Trade Date Time: | 05/14/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.63 | $9.29 | $9.34 | $9.64 | $9.28 | 3,321 | 05-14-2024 |
$9.34 | $9.59 | $9.34 | $9.62 | $9.34 | 1,435 | 05-13-2024 |
$10 | $9.9698 | $10 | $10.2 | $9.4 | 2,927 | 05-10-2024 |
$9.6882 | $9.33 | $9.6882 | $9.6882 | $9.33 | 1,057 | 05-09-2024 |
$9.5001 | $9.5 | $9.5001 | $9.5306 | $9.5 | 1,420 | 05-08-2024 |
$9.66 | $9.56 | $9.66 | $9.66 | $9.56 | 428 | 05-07-2024 |
$9.725 | $9.79 | $9.725 | $9.95 | $9.59 | 1,880 | 05-06-2024 |
$10 | $9.84 | $10 | $10 | $9.371 | 1,529 | 05-03-2024 |
$9.9999 | $9.37 | $9.9999 | $9.9999 | $9.37 | 3,355 | 05-02-2024 |
$10.45 | $9.8 | $10.45 | $10.45 | $9.8 | 1,078 | 05-01-2024 |
$9.77 | $9.36 | $9.77 | $9.77 | $9.36 | 1,158 | 04-30-2024 |
$9.91 | $9.91 | $9.91 | $9.91 | $9.91 | 1,264 | 04-29-2024 |
$9.8003 | $9.53 | $9.8003 | $9.94 | $9.53 | 1,703 | 04-26-2024 |
$10.45 | $9.59 | $10.45 | $10.71 | $9.42 | 4,437 | 04-25-2024 |
$9.83 | $9.73 | $9.83 | $9.89 | $9.625 | 2,744 | 04-24-2024 |
$9.6 | $9.6912 | $9.6 | $9.6912 | $9.6 | 794 | 04-23-2024 |
$9.92 | $9.95 | $9.92 | $9.95 | $9.92 | 889 | 04-22-2024 |
$10 | $9.3499 | $10 | $10.18 | $9.3297 | 6,272 | 04-19-2024 |
$9.33 | $9.3299 | $9.33 | $9.7 | $9.27 | 3,548 | 04-18-2024 |
$10.17 | $10.12 | $10.17 | $10.55 | $10.01 | 9,820 | 04-17-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pharming Group N.V. Company Name:
PHAR Stock Symbol:
NASDAQ Market:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disea...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leid...